The Next Patient · Short read · October 5, 2026
More weight loss—but what’s the tradeoff?
Lilly reported a 48-week trial of an experimental pairing: eloralintide plus tirzepatide. At the highest combination dose, estimated average weight loss was 23.3%, compared with 14.8% on tirzepatide alone. The phase 2b study involved adults with obesity or overweight and type 2 diabetes.
The tradeoff was tolerability. More participants stopped combination treatment because of side effects. The headline estimate assumes participants remained on treatment; it is not a promise of an individual result. This combination remains investigational.
Our take: Weight-loss treatment is already part of everyday health conversations. The useful question is not just how much weight a medicine can help people lose, but whether they can stay on it. This trial makes that question more concrete.